Drugs / EGF-PTI
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03623750 | Jul 2018 → Mar 2020 | non-small cell lung carcinoma | Instituto Oncológico Dr Rosell | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGF-PTI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03623750 ↗ |
| Modality | Vaccine | “Immunisation with EGF-PTI will commence 3 days after low dose cyclophosphamide and commencement of EGFR TKI, and will be repeated on Day 14, Day 28, Day 43, and Day 92.” NCT03623750 ↗ |